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Abstract The pathophysiology of traumatic brain (TBI) in-
jury involves changes to glucose uptake into the brain and its
subsequent metabolism. We review the methods used to study
cerebral glucose metabolism with a focus on those used in
clinical TBI studies. Arterio-venous measurements provide a
global measure of glucose uptake into the brain. Microdialysis
allows the in vivo sampling of brain extracellular fluid and is
well suited to the longitudinal assessment of metabolism after
TBI in the clinical setting. A recent novel development is the
use of microdialysis to deliver glucose and other energy
substrates labelled with carbon-13, which allows the metabo-
lism of glucose and other substrates to be tracked. Positron
emission tomography and magnetic resonance spectroscopy
allow regional differences in metabolism to be assessed. We
summarise the data published from these techniques and
review their potential uses in the clinical setting.
Keywords 13C labelling . Glucose .Magnetic resonance
spectroscopy .Microdialysis .Positronemission tomography .
Traumatic brain injury
Introduction
Traumatic brain injury (TBI) is heterogeneous disorder caused
by the action of external mechanical forces on the brain. It is
one of the leading causes of mortality in young adults with
mortality rates in the USA and Europe ranging between 15 and
20 per 100,000 per annum (Tagliaferri et al. 2006; Maas et al.
2008). TBI incidence is increasing worldwide. In developing
countries this is due to increasing use of motorised vehicles,
while in developed nations there is an increasing incidence of
TBI in the older population due to falls (Roozenbeek et al.
2013). Moreover, it is estimated that approximately 5.3 and
7.7 million people are living with disability due to TBI in the
USA and Europe respectively (Roozenbeek et al. 2013). TBI
thus has huge economic and societal costs.
The primary injurious event is followed in the hours and
days after injury by secondary pathological processes that can
exacerbate damage, and are thus targets for therapy. The man-
agement of TBI centres on the maintenance of adequate cere-
bral blood flow (CBF) and the delivery of sufficient glucose
and oxygen to preserve tissue not irreparably damaged by the
initial physical insult. Thus, cerebral perfusion is maintained,
hypoxia avoided, and with modern neurocritical care manage-
ment, secondary ischaemia is not thought to play a major role.
However, despite progress in management of TBI patients,
many still suffer long-term or lifelong disabilities, thus placing
heavy demands on carers and healthcare resources, and there is
scope for better treatments (Kolias et al. 2013).
Increasingly recognised are the cellular perturbations that
challenge energy metabolism in TBI. The following changes
have been revealed by experimental studies. Disruption to cell
membranes and a failure tomaintain normal ionic homeostasis
results in cytotoxic oedema, which further challenges mem-
brane integrity (Unterberg et al. 2004). Excitotoxic release of
glutamate and other excitatory neurotransmitters exacerbate
the disturbance of trans-membrane ionic gradients (Katayama
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et al. 1990; Kawamata et al. 1992). Mitochondrial calcium
accumulation induces oxidative stress and impairs mitochon-
drial function (Xiong et al. 1997; Osteen et al. 2004). The
generation of free radicals, highly reactive oxygen and nitro-
gen species, normally kept in check by cellular antioxidant
systems, leads to the oxidative modification of proteins, lipids
and DNA (Hall et al. 1993; Marklund et al. 2001). This results
in increased permeability of the inner mitochondrial mem-
brane, release of cytochrome c leading to caspase-dependent
apoptosis, and activation of poly-ADP ribose polymerase
(PARP), a nuclear DNA repair enzyme that consumes NAD+,
a coenzyme essential for glycolysis (Sullivan et al. 1998;
Lewén et al. 2001; Satchell et al. 2003). Ultimately, although
initially potentially reversible, these metabolic and mitochon-
drial perturbations, result in energy failure and activation of
both apoptotic and necrotic pathways (Lewén et al. 2001).
These and other, as yet uncharacterised changes may be im-
portant in TBI patients’ brains. The pathophysiology of energy
failure after TBI is not yet fully understood but has important
implications for howTBI patients are managed. Improving our
understanding of these metabolic disturbances will help lead to
strategies that reduce secondary injury and improve outcomes.
The metabolic perturbations that result from TBI have large-
ly been studied using animal models of TBI (Andersen and
Marmarou 1992; Xiong et al. 2013). In general, for the purposes
of metabolic studies, metabolites are measured and/or tracers
are used to follow biochemical processes at set time points after
experimental injury. Many of the techniques used require the
brain to be extracted and so are not applicable in clinical studies.
Animal models of TBI produce a relatively homogenous injury
in comparison to clinical TBI and the majority of studies do not
consider co-morbidities or other systemic factors that frequently
complicate clinical TBI. Patients with severe TBI commonly
have injuries to other organs, such as chest and abdominal
injuries, with consequent risk of systemic hypoxia and/or hy-
potension, which is deleterious to outcome (Chesnut et al. 1993;
Stocchetti et al. 1996). The impact of sedative drugs and other
pharmaceutical agents, which also likely influence cerebral
metabolism, are also frequently overlooked. Hence, we have
to be careful in applying what we learn about glucose metabo-
lism after TBI in the laboratory to what actually happens in
clinical practice. For an in-depth review of experimental TBI
models, see (Xiong et al. 2013).
There are various methods for investigating metabolism after
TBI in patients (Fig. 1). Measuring arterial, jugular and/or
cerebrospinal fluid (CSF) concentrations of metabolites pro-
vides a measure of how much the brain as a whole imports or
exports. Microdialysis, which samples extracellular fluid, is a
focal technique that allows the immediate microenvironment of
the brain to be sampled in vivo. Microdialysis can also be used
to deliver substances and in this way has been used to deliver
glucose and other metabolites labelled with carbon-13 (13C).
This is combined with ex vivo nuclear magnetic resonance
(NMR) spectroscopy of the microdialysis-collected extracellular
fluid yielding information on different intracellular pathways.
Autoradiography experiments in animals, and analogous posi-
tron emission tomography (PET) studies in humans, use glucose
labelled with a radioactive tracer. These experiments allow
regional differences in glucose uptake and metabolism to be
measured. In vivo magnetic resonance spectroscopy (MRS) has
also been used to measure the combined extra- and intracellular
regional concentrations of lactate and high-energy phosphate
compounds. Our ability to study cerebral metabolism using
these techniques has greatly improved our understanding of
Fig. 1 Methods for measuring glucose metabolism in the human brain:
Various techniques lend themselves to measuring glucose metabolism in
the human brain. (1) Microdialysis, which allows metabolites in the
extracellular fluid to be measured, is an invasive technique requiring
insertion of a microdialysis catheter (possessing a semipermeable mem-
brane, with nominal molecular weight cut-off typically 20 kDa or
100 kDa) into brain parenchyma. A pump is used to infuse perfusion
fluid at a low flow rate (e.g. 0.3 μl/min) into the catheter and returned
microdialysate is collected into small vials for subsequent analysis. (2)
Imaging techniques include positron emission tomography (PET), which
uses detectors to measure ionising radiation emitted from the glucose
analogue FDG administered intravenously. This provides a measure of
the uptake and phosphorylation of glucose. (3) 1H and 31P magnetic
resonance spectroscopy (MRS) can be used to measure lactate and
high-energy phosphate compounds respectively, in different regions of
the brain. (4) A global measure of uptake or release from the brain can be
achieved by using a jugular bulb catheter, which allows the venous
outflow of the brain to be sampled. Measured concentrations in blood
sampled from the venous catheter can be compared with arterial concen-
trations of metabolites, typically measured in blood taken from an arterial
line. This enables the net uptake or release of metabolites by the brain to
be calculated and, if cerebral blood flow is known, the cerebral metabolic
rate to be calculated
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the pathophysiology of TBI. Importantly, there is also the po-
tential for these techniques to help in themanagement of patients
with TBI and improve clinical outcomes although their role in
the clinical setting is still being defined.
The aim of this review is to summarise what we know
about the metabolic perturbations that characterise TBI with a
focus on clinical studies. Specifically, we will focus on chang-
es to glucose metabolism after moderate to severe TBI. See
Fig. 2 for an overview of glucose metabolism. The most
noticeable feature is that the injured brain can exhibit a relative
rise in non-oxygen-consuming glucose metabolism. With the
increasing clinical availability of techniques that provide in-
sight into glucose metabolism, such as microdialysis and
MRS it is important to review the available evidence with a
view to improving our ability to interpret this data.
Arterio-venous gradient studies
Arterio-venous (AV) studies provided the first means for
studying human cerebral energy metabolism. This was first
achieved when Kety and Schmidt (1948) applied the Fick
principle to calculate CBF and cerebral oxygen consumption.
The amount of substance that a tissue removes from or re-
leases into the circulation is equal to the product of the blood
flow to the tissue and the arterio-venous (AV) concentration
difference. Using this principle, the steady-state rate of
utilisation or production, known as the cerebral metabolic rate
(CMR), can be calculated.
AV studies investigating the CMR of glucose (CMRglc)
after TBI demonstrate a depression in CMRglc indicating re-
duced glucose uptake and utilisation by the injured brain (Cruz
1995; Leegsma-Vogt et al. 2001; Glenn et al. 2003). Glenn et al.
(2003) compared 49 TBI patients with 31 awake volunteers and
used AV difference measurements and a Xenon-133 clearance
technique to calculate CBF. Amean CMRglc of 4.46±1.16mg/
100 g/min was found in normal subjects whereas this was
significantly lower in TBI patients who had a mean CMRglc
of 3.43±2.32 mg/100 g/min during post-injury days 0 to 5.
Alongside this global depression in glucose metabolism,
Glenn et al. (2003) found a significant depression in oxygen
metabolism. They calculated the metabolic ratio (MR) by
calculating CMRO2/CMRglc (in molar units) and found that
this was significantly lower in TBI patients compared to
normal subjects. The MR in normal subjects was 5.83±1.41,
which demonstrates the efficiency of the brains aerobic me-
tabolism of glucose. Six moles of oxygen are needed for the
oxidation of one mole of glucose hence a MR value close to 6
indicates almost complete aerobic metabolism of glucose. A
MR value greater than 6 implies aerobic metabolism of other
substrates, and less than 6 the anaerobic metabolism of glu-
cose. Other substrates potentially metabolised by the injured
brain that would in theory account for an MR greater than 6
include lactate (see below) and ketone bodies (Prins and Giza
2006). Further non-glucose substrates for brain could include
fatty acids, although a recent review has argued against fatty
acids being a good brain energy source (Schönfeld and Reiser
2013). In the TBI patients the MR was 4.11±2.11, i.e. more
moles of glucose metabolised per mole of oxygen, which
indicates that there is proportionally greater “anaerobic”
(non-oxygen-consuming) metabolism of glucose. In several
patients a MR of less than 3.44 was observed and this was
interpreted as indicating ‘relative hyperglycolysis’; propor-
tionally much greater anaerobic glucose metabolism than aer-
obic, although only a small proportion of samples (5 %) dem-
onstrated absolute hyperglycolysis with an elevated CMRglc.
In a similar metabolic ratio calculation based on AV difference
of oxygen and glucose measurements in 69 TBI patients,
which they termed the oxygen-glucose index (OGI), Holbein
et al. (2009) found values mostly above 6 in 69 TBI patients
suggesting maintained aerobic metabolism of glucose. How-
ever, higher arterial glucose levels were associatedwith greater
“anaerobic” (non-oxygen-consuming) glucose metabolism.
As well as perturbations to the relationship between cere-
bral glucose and oxygen metabolism, the metabolism of lac-
tate is also affected by TBI. AV measurements in healthy
controls reveal a small net release of lactate from the brain
into the circulation (Glenn et al. 2003; Larsen et al. 2008).
However, several authors have revealed periods during which
AV measurements indicate uptake of lactate by the injured
brain after TBI (Glenn et al. 2003; Meierhans et al. 2012;
Jalloh et al. 2013). Jalloh et al. (2013) examined AV gradients
in 19 patients with diffuse TBI and found periods of lactate
uptake in 17 of these patients. This was associated with
maintenance of normal AV glucose measurements. The like-
lihood is that, after TBI, lactate from the circulation is taken up
by the injured brain and used as a metabolic substrate.
Supporting this concept, intravenous administration of 14C-
lactate to a rodent TBI model demonstrated accumulation of
radiolabel at the injury site (Chen et al. 2000). Moreover, in
humans, lactate labelled with 13C and delivered to the brains
of TBI patients by microdialysis is metabolised via the TCA
cycle to glutamine (Gallagher et al. 2009).
AV studies provide a measure of the uptake or release of
substance by the whole brain at a single time point; they lack the
spatial and temporal resolution to explore how changes to
glucose metabolism relate to other pathophysiological changes.
Moreover, given the heterogeneity of TBI this techniquewill not
detect metabolic differences between injured and non-injured
areas of brain. Another important consideration when using this
method is that jugular venous samples are not representative of
the entire brain; only one vein is sampled excluding contralateral
and extra-jugular venous drainage (Ferris and Engel 1946).
These limitations and the difficulty of obtaining reliable venous
oxygen saturation measurements means that they are not used
routinely in clinical practice (Pattinson et al. 2005).
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Fig. 2 Glycolysis and the tricarboxylic acid cycle: Glucose is the pre-
ferred substrate for the brain, although the brain can take up lactate, other
monocarboxylic acids and ketone bodies under certain circumstances, for
example, during the perinatal period. Once it enters cells, glucose is
metabolised through glycolysis to pyruvate. Glycolysis (also termed
Embden-Meyerhof pathway) is the series of reactions that results in the
breakdown of glucose, generating pyruvate, adenosine triphosphate
(ATP) and nicotinamide adenine dinucleotide (NADH). It is a truly
fundamental pathway, found throughout nature and proceeds without
the need for oxygen. The ten key enzymatic steps, in which 2 ATP
molecules are consumed early on but then paid back later with the
generation of 4 ATP molecules per glucose molecule, so the net produc-
tion of ATP is 2 molecules per molecule of glucose, takes place in the
cytoplasm. There are three key regulatory points catalysed by the en-
zymes hexokinase, phosphofructokinase, and pyruvate kinase. These
reactions are essentially irreversible whereas the other enzymatic steps
exist in equilibrium. Pyruvate is converted to acetyl CoA, which enters
the tricarboxylic acid (TCA) cycle, within mitochondria. The TCA cycle
results in the transfer of electrons (fromNADH and succinate), to electron
transport chains (ETC.) located in the inner mitochondrial membrane,
which ultimately deposit on oxygen molecules. Thus the TCA cycle
generates carbon dioxide (also generated by the pyruvate dehydrogenase
step prior to TCA cycle) and the ETC generates water. The ETCs pump
protons across the inner mitochondrial membrane, maintaining a gradient
of protons across the membrane. Protons then flow down their concen-
tration gradient, through ATP synthetases (ATPase), resulting in the
generation of ATP, the cells’ widely used energy currency. Energy pro-
duction from glucose is intrinsically related to neurotransmission. Gluta-
mate spins off the TCA cycle from α-ketoglutarate (αKG), an interme-
diate of the TCA cycle. Glutamate can be converted reversibly into
glutamine. Glutamate can also be converted into gamma-aminobutyric
acid (GABA). There is a constant cycle of glutamate released during
neurotransmission, retrieved from synaptic junctions by astrocytes and
returned to neurons as glutamine
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Microdialysis
Microdialysis allows continuous in vivo sampling of mole-
cules from the extracellular fluid from the human brain and
permits the longitudinal analysis of certain energy-related
small molecules. Clinical microdialysis catheters are often
inserted alongside brain tissue oxygen sensors such that
changes in concentrations of small molecules related to energy
metabolism can be monitored in conjunction with variations
in tissue oxygen levels. Metabolic features of microdialysates
statistically associated with adverse outcomes after TBI in-
clude high concentrations of lactate and high lactate/pyruvate
ratio, while for glucose the situation appears more complex
with both high and low concentrations having adverse asso-
ciations. Further details are as follows.
Patients with poorer outcomes after TBI have been ob-
served to have lower average glucose concentrations for the
monitoring period compared to those with better outcomes
although the relationship is complex and high glucose con-
centrations are also associated with worse outcomes (Zauner
et al. 1997; Vespa et al. 2003; Timofeev et al. 2011a; Yokobori
et al. 2011). Vespa et al. (2003) identified three patterns of
daily mean glucose concentrations in 30 patients with severe
TBI. They found better outcomes when the glucose concen-
tration was initially ‘normal’ and then later declined as op-
posed to initially low at the start of their monitoring (Fig. 3).
They also found the lowest overall mean glucose in the
patients that had the worse outcomes, although, no indepen-
dent effect of low glucose was observed using a multivariate
model with other known predictors. Similarly, Yokobori et al.
(2011) found that glucose gradually declines until the fourth
day after the onset of monitoring and then increases. The
largest investigation of TBI patients to date found that the
total averaged monitoring glucose concentration was a posi-
tive predictor of mortality in a multivariate model such that
higher concentrations of glucose were associated with mortal-
ity (Fig. 3) (Timofeev et al. 2011a). Hence, the likelihood is
that there is an optimum range for cerebral glucose with both
low and high glucose having been associated with worse
clinical outcomes.
Low brain glucose after TBI might be attributable to is-
chaemia, i.e. a deficiency in supply of oxygen, glucose and
other blood-borne nutrients. Nowadays, with modern
protocol-driven therapy, the incidence of gross ischaemia after
TBI is low in neurocritical care patients. The injured brain
may however be at risk frommicro-vascular ischaemia, failure
of vascular autoregulation, elevated intracranial pressure, and
systemic problems that result in hypoxia and/or hypotension
(Chesnut et al. 1993; Marmarou et al. 2009; Timofeev et al.
2011b; Newcombe et al. 2013). Because of the confounding
effects of a reduced conscious level and sedative drugs after
TBI ischaemic thresholds cannot simply be determined by
CBF measurements. Instead an increase in the oxygen
gradient across the brain is used to indicate a relative supply
failure. This can be measured globally using jugular venous
oxygen saturations and regionally using PET. Coles et al.
(2004) used Oxygen-15 (15O) PET to measure oxygen extrac-
tion fraction (OEF) and to define ischaemic voxels. They
based their OEF ischaemia threshold on a venous oxygen
threshold of 3.5 ml/100 ml and estimated the volume of
ischaemic brain in 15 TBI patients within 24 h of TBI. They
found ischaemic volumes of between 1 and 16 % of the total
brain volume, particularly in voxels adjacent to contusions or
haematomas. Vespa et al. (2005), using similar methodology
and the same OEF threshold in 19 patients found that the
incidence of ischaemic voxels averaged only 0.14±0.28 %,
although patients underwent PET imaging at later time points;
on average 60±30 h from injury. In the same study, using a
different threshold based on an OEF greater than 0.75 (a value
based on previous 15O PET studies performed in patients with
ischaemic stroke) they found the mean incidence of ischaemic
voxels was 0.11±0.18 % with a maximum of 1 % of voxels in
a single patient. Furthermore, no significant correlation was
found between microdialysis-measured brain glucose and
PET measured CBF or OEF. Interestingly, in areas of brain
deemed to be at risk of non-survival, defined as 15O PET-
measured oxygen metabolism below a critical threshold,
normobaric hyperoxia increases oxygen metabolism but does
not have a consistent effect on microdialysis measures of
metabolism (Nortje et al. 2008).
Although the incidence of frank ischaemia after TBI ap-
pears to be low, marked changes to CBF, induced by hyper-
ventilation, or marked reductions in cerebral perfusion pres-
sure (CPP) can affect brain glucose. Hutchinson et al. (2002)
combined triple oxygen PETwith microdialysis and found no
significant correlation between CBF and brain microdialysate
glucose in 17 patients with TBI. However, during periods of
hyperventilation, which significantly increased the OEF, a
significant reduction of brain glucose was observed. Hlatky
et al. (2004) found that in a subset of 57 patients with TBI who
experienced a marked reduction in CPP, due to high intracra-
nial pressure (ICP) or systemic hypotension, there was a fall in
brain glucose. This was paralleled by a fall in brain tissue
oxygen reflecting the tissue ischaemia.
A reduction in brain glucose after TBI is partly a conse-
quence of greater cellular uptake and utilisation, reflected by
elevation of downstream metabolites. Pyruvate and lactate are
both derived from glucose and so their extracellular
concentrations partly reflect glycolytic activity. In turn, the
relative proportions of lactate and pyruvate, the lactate/
pyruvate ratio, reflects the degree that glycolytically produced
pyruvate is subsequently metabolised oxidatively within the
mitochondria via the TCA cycle or anaerobically in the cyto-
sol to lactate. A greater lactate/pyruvate ratio indicates a
greater proportion of glycolytic metabolism in relation to
mitochondrial oxidative metabolism. Timofeev et al. (2011a)
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in the largest study to date found the most consistent trends
of all the microdialysis parameters measured after TBI were
for brain lactate and the lactate/pyruvate ratio both of which
were lower on a daily basis in patients with favourable out-
come as compared with those patients with a poor outcome.
Moreover, the lactate/pyruvate ratio was found to be a signif-
icant positive predictor and pyruvate a significant negative
predictor of mortality. The association of a higher lactate and
higher lactate/pyruvate ratio with a poor outcome is a consis-
tent finding across the TBI-microdialysis literature and is
found in the most methodologically robust of studies that
use patient-averaged data and multivariate statistical tech-
niques (Timofeev et al. 2011a; Paraforou et al. 2011; Stein
et al. 2012).
Fig. 3 Pattern of declining
microdialysate glucose after TBI:
Upper panel: Graph showing
initially ‘normal’ followed by
declining mean microdialysate
glucose concentrations after post-
injury day 5 in those patients who
went on to have a good outcome
(Glasgow Outcome Scale
extended (GOSe) 5 to 8).
Figure originally published in the
Journal of Cerebral Blood Flow&
Metabolism (Vespa et al. 2003).
Lower panel: Pooled
microdialysis glucose
concentrations averaged by day of
monitoring and split by outcome
categories demonstrating
declining median concentrations
over the course of a week of post-
injury monitoring.
Figure originally published in
Brain (Timofeev et al. 2011a)
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The association between high microdialysate lactate and
poor outcome might seem, taken at face value, at odds with
increasing evidence for lactate’s role as an energy substrate.
However, this apparent contradiction may be explained by
uncoupling of neuronal and glial metabolism. Animal studies
have provided evidence for brain utilisation of intravenously
administered 3-13C lactate via the TCA cycle (Tyson et al.
2003). In human brain, direct evidence for utilisation of lactate
via the TCA cycle, in TBI patients, has been obtained in a
cerebral microdialysis study in which 3-13C lactate was in-
fused directly into brain via the microdialysis catheter
(Gallagher et al. 2009). A recent intravenous lactate supple-
mentation study in TBI patients revealed evidence for a ben-
eficial effect judged by surrogate endpoints (Bouzat et al.
2014). Lactate has conventionally been regarded as a waste
product of glucose metabolism, though a more recent idea is
that neurons take up and metabolise lactate that has been
generated by astrocytes. This has become known as the
astrocyte-neuron lactate shuttle hypothesis (Pellerin and
Magistretti 1994). Low extracellular lactate levels, associated
with better outcomes (Timofeev et al. 2011a), might be be-
cause astrocyte-derived glycolytic lactate is efficiently taken
up by neurons and utilised via the TCA cycle (Gallagher et al.
2009). Conversely, where neurons are too damaged to utilise
the lactate produced from glucose by astrocytes, i.e.
uncoupling of neuronal and glial metabolism, high extracel-
lular levels of lactate would accumulate, explaining one po-
tential mechanism behind the association between high extra-
cellular lactate and poor outcome (Carpenter et al. 2014).
In support of brain glucose concentrations being influenced
by uptake and cellular utilization, a combined 18F-fluoro-
deoxyglucose-PET (FDG-PET) and cerebral microdialysis
study in TBI patients found that the CMRglc measurements
in a 2 cm region of interest around the microdialysis catheter
tip showed significant positive correlations of CMRglc with
lactate and pyruvate concentrations, no relationship between
CMRglc and L/P ratio, and a weak inverse trend for CMRglc
with glucose concentrations in the microdialysates (Fig. 4)
(Hutchinson et al. 2009). Thus low concentration of brain
extracellular glucose seems a consequence of increased sub-
strate demand rather than inadequate substrate delivery. A
caveat is that at low brain glucose concentrations there is a
risk of underestimating lumped constant and hence of
overestimating CMRglc in such situations. The main conclu-
sion of the study is that in TBI brain an increase in glucose
metabolism leads to increases in both lactate and pyruvate, as
opposed to a shift towards anaerobic metabolism. For further
discussion of PET in the context of cerebral metabolism see
“Autoradiography and positron emission tomography” sec-
tion below.
Brain glucose reflects systemic glucose levels, glycaemic
control and the use of insulin in TBI patients. Several studies
have explored the relationship between systemic glucose and
brain microdialysis parameters in TBI patients and found that
higher arterial glucose concentrations are associated with
higher brain glucose concentrations although this relationship
may be lost when the brain is injured (Vespa et al. 2006;
Meierhans et al. 2010; Rostami and Bellander 2011). Further-
more, systemic glucose has an influence on other microdialy-
sis parameters. Meierhans et al. (2010) observed that arterial
glucose concentrations greater than 6 mmol/L were associated
with both higher brain microdialysate glucose and glutamate
concentration. Diaz-Parejo et al. (2003) observed that epi-
sodes of pronounced hyperglycaemia (greater than 15 mmol/
L) were associated with greater brain lactate. The relationship
between systemic glucose and cerebral metabolism has also
been explored using AV measures of metabolism. Holbein
et al. (2009) observed increased glucose uptake, decreased
lactate export and reduced oxygen consumption by the brain
at higher arterial glucose concentrations. The retrospective
nature of these studies limits our ability to be clear about
how changes in systemic glucose concentrations affect cere-
bral metabolism or to clearly define an optimal systemic
glucose concentration for TBI patients. In a prospective study,
Vespa et al. (2012) randomised 13 TBI patients using a within-
subject crossover design to tight (80–110 mg/dL) versus loose
(120–150 mg/dL) glycaemic control and assessed metabolism
using both microdialysis and FDG-PET. They observed that
microdialysate glucose, pyruvate and lactate were significant-
ly lower, that more time was spent with a high lactate/pyruvate
ratio (>28), and that FDG-PET indicated increased glucose
metabolism (although in a heterogeneous manner depending
on the patient and injury pattern) when tight glycaemic control
was used. Hence, loose glycaemic control was interpreted as
being preferable for cerebral metabolism.
In summary, microdialysis parameters can be difficult to
interpret due to the various factors that influence the extracel-
lular concentrations of metabolites. Trends of values and
ratios, as opposed to single values, are more clinically useful
in predicting clinical outcomes and for guiding treatments.
Moreover, microdialysis is a focal technique limited to sam-
pling a small area of brain. Data from microdialysis should be
interpreted with this in mind; peri-contusional brain expresses
a different metabolic profile to macroscopically normal brain.
However, the relative ease of placement, safety and ability to
follow trends in brain chemistry over extended periods of time
has resulted in the adoption of microdialysis as a clinical
monitoring tool in many neurocritical care units.
Autoradiography and positron emission tomography
Autoradiography and PET imaging studies that use labelled 2-
deoxy-D-glucose (2DG) as a tracer allow the in vivo delivery,
uptake and initial metabolism of glucose to be assessed both
globally and regionally in the brain. Demonstration of this
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technique by Sokoloff et al. (1977) provided some of the first
experimental techniques for interrogating regional changes in
cerebral metabolism in vivo. They used 2-deoxy-
D-[14C]glucose as a tracer ([14C]DG), which is taken up from
the circulation and phosphorylated by hexokinase in the first
stage of glycolysis. [14C]DG, following phosphorylation, does
not continue in the next and subsequent steps of glycolysis,
essentially remaining trapped. Sokoloff et al. (1977) injected
awake and anaesthetised rats with the tracer and used
quantitative autoradiography of brain sections to calculate
regional rates of glucose metabolism.
The principles of the autoradiography techniques devel-
oped by Sokoloff et al. (1977) have been adapted for use in
humans with PET imaging. PET is a tomographic technique
that involves measuring the accumulation of radiolabel in
tissue following injection of labelled compound into the cir-
culation. For the purposes of exploring regional glucose me-
tabolism, the patient is injected with deoxy-glucose, labelled
with the positron emitter 18F (FDG) (Phelps 1991). The emit-
ted positrons are measured using a ring-shaped array of de-
tectors (scintillator crystals and photomultipliers) and then
algorithms used to reconstruct the location and local
Fig. 4 FDG-PET measurement of CMRglc and its relationship to brain
microdialysate composition: a–c FDG-PET CMRglc map demonstrating
relatively high FDG uptake at sites of injury, in contrast to less injured
areas of the brain. aComputed tomography (CT) scan showing gold tip of
microdialysis catheter (indicated by arrow). b Co-registered FDG-PET
CMRglc map showing high FDG uptake at sites of injury. c Overlay of
CT and co-registered CMRglc map, showing microdialysis catheter tip
location (arrow). (d–f Graphs illustrating relationships by linear regres-
sion (for 22 ROIs in 17 TBI patients) between FDG-PET derived
CMRglc and the microdialysis parameters measured during the scan (d)
lactate, (e) pyruvate, (f) lactate/pyruvate (L/P) ratio, and (g) glucose. For
the linear regressions in (d–g), corresponding values of p (ANOVA) are
<0.0001, <0.0001, 0.74 and 0.48 respectively. Data-points from catheters
at craniotomy sites (4 patients) are differentiated by grey triangles. Data-
points from a second FDG-PET scan (one patient) are differentiated by
grey diamonds. All other data-points are depicted as black circles (cath-
eters inserted via cranial access device). Linear regressions presented on
the graphs are for the entire (combined black plus grey symbols) dataset
consisting of all 22 ROIs. Figure originally published in Acta
Neurochirurgica (Hutchinson et al. 2009)
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concentration of radioisotopes. Rate constants relating to the
movement of tracer between the circulation, extracellular space
and the intracellular compartment are used with the plasma
glucose concentration and a ‘lumped constant’ to give a mea-
sure of themetabolic rate of glucose. The lumped constant (LC)
of Sokoloff et al. (1977) accounts for the differences in trans-
port and phosphorylation rates between D-glucose and 2DG.
2DG ismore readily transported into the cell whereas glucose is
more readily phosphorylated by hexokinase. However, there is
no universal value for LC and values may differ between
centres or even within-centre at different times. While many
studies have assumed that the LC is uniform over the whole
brain and in different states of disease or conscious level, this is
not necessarily the case. Marklund et al. (2009) demonstrated
regional differences in the uptake of 14C-glucose relative to
2DG in rats after experimental TBI, suggesting regional differ-
ences in LC, and Wu et al. (2004) showed that the global LC
value was significantly lower in TBI patients compared with
normal controls. Furthermore, various mathematical models
have been used to calculate CMRglc from the PET data. These
include the Huang autoradiographic model and dynamic
methods such as Patlak graphical analysis and full kinetic
modellingwith 3 or 4 rate constants (termed 3 k or 4 kmethods)
(Huang et al. 1980; Patlak and Blasberg 1985) (Lammertsma
et al. 1987). The different models apply different rate constants,
which are either pre-defined (standard, as in the Huangmethod)
or estimated from the FDG-PET data (as in the dynamic
methods). Another approach is statistical parametric
mapping to compare FDG uptake in different areas of
the brain without calculating absolute CMRglc values (Zhang
et al. 2010). Hence, it is not necessarily straightforward to
compare FDG-PET quantitative results between studies per-
formed in different centres, or within the same centre at
different times.
Autoradiography and PET studies in animals have demon-
strated a stereotyped acute period of high glucose metabolism
followed by longer lasting metabolic depression. This acute
period of hypermetabolism is observed in animal models for
up to 6 h, and affects both hemispheres but more so on the
ipsilateral hemisphere (Sunami et al. 1989). Following this
acute period of hypermetabolism, a depression in glucose
metabolic activity ensues that may last several weeks. This
appears to be widespread throughout various regions of the
brain and has been found to be associated with neurological
outcome in clinical studies (Kato et al. 2007).
Most clinical reports demonstrate a depression of glucose
metabolism following TBI when compared to control subjects
with only discrete areas of supra-normal glucose metabolism,
particularly in relation to mass lesions (Fig. 4). Bergsneider
et al. (2000) observed that 20 of 26 (77 %) patients with a
range of TBI severities within seven days post-injury demon-
strated a CMRglc in cortical grey matter of the whole brain at
least two standard deviations lower than a value for CMRglc
derived from a historical control group (7.3±1.2 mg/100 g/
min). There was no clear correlation between the severity of
injury and CMRglc values although patients that were on dual
sedative drugs (morphine and a benzodiazepine) exhibited
lower CMRglc values than those on a single sedative. Some
peri-contusional cortical grey matter areas demonstrated
markedly raised CMRglc values compared to the control
value whereas others demonstrated depressed CMRglc. A
later study from the same group, which used aged-matched
controls and LC values calculated from a cohort of subjects
who underwent additional arterio-venous 2DG gradient mea-
surements, used to estimate a global LC value, found signif-
icantly lower CMRglc in the whole brain, striatum and thala-
mus in TBI patients compared to control subjects (Hattori
et al. 2003). No differences were detected in the brainstem
or cerebellum. Of note, whole brain CMRglc in control sub-
jects in this study was 3.8±0.7 mg/100 g/min, which was
considerably lower than the value previously calculated from
a historical cohort study.
Although glucose metabolism in TBI patients is found to be
relatively depressed compared to awake and non-sedated con-
trol subjects, PET studies suggest that glucose metabolism in
TBI is increased relative to the rate of oxygen utilisation. In a
subset of six patients undergoing FDG-PET Bergsneider et al.
(1997) used a combination of arterio-venous oxygen measure-
ments and intravenous Xenon-133 CBF measurements to cal-
culate both oxygen and glucose metabolism. In all six of these
patients, who underwent FDG-PET imaging between days 2
and 8 post-injury, glucose metabolism was found to be dispro-
portionately greater than oxygen metabolism, so termed
‘hyperglycolysis’. Wu et al. (2013) combined triple-oxygen
(15O) PET, used to measure regional oxygen utilisation, with
FDG-PET to explore the relationship between glucose and
oxygenmetabolism in contusional and peri-contusional regions
in eight TBI patients. CMRglc in contusional and peri-
contusional regions was depressed relative to CMRglc mea-
sured in the surrounding normal-appearing white matter of the
same patient. Moreover, oxygen metabolism was even more
depressed suggesting a shift in glucose metabolism from oxy-
gen consuming to anaerobic metabolism.
The changes in glucose metabolic activity observed with
deoxy-glucose studies relate to both the rate of glucose trans-
port into cells and the rate of phosphorylation by hexokinase.
Whether the changes in glucose metabolic activity that follow
TBI are caused by changes in glucose transport, changes in
hexokinase activity or are due to a combination of both
changes in transport and hexokinase activity is not readily
appreciated by autoradiography studies. Manipulating the
mathematical models used in order to try and separate out
these different aspects suggests that glucose transport activity
is impaired in peri-contusional areas only whereas hexokinase
activity is impaired more globally (Hattori et al. 2003; Wu
et al. 2004).
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Whether blood brain barrier (BBB) permeability impacts
significantly on glucose metabolism in TBI patients is as yet
unknown. A leaky BBB might conceivably allow more circu-
lating glucose to enter the brain, while damaged cells might
have less efficient specific transporters and/or exhibit a more
glycolytic phenotype. In a microdialysis comparison of sites
in TBI patients’ brains, glucose had a tendency to be lower in
peri-lesional sites than in less-injured sites, while lactate/
pyruvate ratio, lactate concentration and pyruvate concentra-
tion were all significantly higher in peri-lesional sites than in
less-injured brain (Timofeev et al. 2011b). Although this was a
large study (97 patients), a limitation of the statistical analysis
was that catheters were not paired within-patient. A much
smaller FDG-PETand microdialysis combined study included
a subset of four patients with paired catheters (Hutchinson
et al. 2009). In that study, the peri-lesional sites had higher
pyruvate and higher regional CMRglc (together with a ten-
dency towards higher lactate) than in the corresponding less-
injured sites, while glucose and lactate/pyruvate ratio were not
significantly different between sites, albeit in this very small
subset of patients. More patients need to be studied for site-
dependent differences, which may shed light on effects of
BBB within the injured brain.
The infrastructure required to generate PET ligands as well
as the ionising nature of the radiation limits their widespread
use as a clinical tool. Furthermore, FDG-PET provides infor-
mation on the uptake of glucose and on the first part of glycol-
ysis but does not evaluate glucose metabolism beyond this.
Carbon-13 labelling studies
Applying a tracer to glucose that can then be identified in
downstream metabolites derived from glucose allows the
metabolic fate of glucose to be evaluated. Classically, this
was achieved with radioisotope labelling using carbon-14
(14C). Due to the ionising nature of 14C these techniques are
not readily applicable to patients. Moreover, most investiga-
tors using 14C-glucose have identified the labelled metabolites
in extracted and purified brains. Carbon-13 (13C) is a naturally
occurring stable isotope with magnetic properties that can be
detected by nuclear magnetic resonance (NMR) spectroscopy
and by gas chromatography–mass spectrometry (GC-MS).
The ability of NMR to identify not only the metabolite but
also the precise intra-molecular position(s) of 13C means that
the relative activity of metabolic pathways can be determined
from the particular labelling patterns observed in metabolites.
See Fig. 5 for an example of labelling patterns observed after
administration of 1-13C glucose and 3-13C lactate.
13C-labelled substrates have been delivered to the brain
intravenously, or directly into the brain extracellular fluid
using microdialysis. For an in-depth review see Carpenter
et al. (2014). These studies have investigated whether the
periods of ‘hyperglycolysis’ observed in studies using AV
measurements or FDG-PET relate to actual increased glycol-
ysis or are due to the metabolism of glucose by other alterna-
tive pathways, and have also investigated the metabolism of
other substrates by the brain such as lactate and acetate
(Gallagher et al. 2009; Carpenter et al. 2014).
13C-labelled glucose administered intravenously to CCI
and FPI rat injury models of TBI, analysed by 13C NMR of
brain tissue extracts, suggest that glucose is metabolised dif-
ferently after TBI with up regulation of the pentose phosphate
pathway (PPP) (Kaibara et al. 1999; Bartnik et al. 2005,
2007). The PPP is potentially an important reparative and
protective pathway for the injured brain. It results in the
production of ribose sugars, needed for DNA synthesis and
repair, and the NADPH generated by the PPP also acts to
maintain glutathione in a reduced state, which serves a vital
antioxidant role (Herrero-Mendez et al. 2009). Dusick et al.
(2007) used intravenously delivered 1,2-13C2 glucose and
used GC-MS to measure the 13C-labelled products in arterial
and jugular venous blood, in six TBI patients and six healthy
controls. Their arterio-venous difference analysis of 13C-la-
belled lactate, differently labelled depending on whether it
was derived by either glycolysis or PPP supported the preclin-
ical finding of PPP up-regulation after TBI.
Examples of 13C NMR spectra of brain microdialysates are
shown in Fig. 6. This includes spectra showing 13C signals for
glutamine C4 after delivery of 13C-lactate to the brains of TBI
patients indicating TCA cycle operation followed by conver-
sion of glutamate to glutamine, which demonstrates that the
injured brain is able to utilise lactate as a metabolic fuel
(Gallagher et al. 2009).
The relatively novel combination of 13C-labelled substrate
delivered by microdialysis with ex vivo NMR has some
important advantages over other methods of studying metab-
olism in the clinical setting. Firstly, the technique has proved
to be safe and easy to use in ventilated sedated TBI patients
and does not require the transfer of the patient to a scanner
(Gallagher et al. 2009). It is relatively inexpensive; only small
amounts of 13C substrates (typically less than 1 g) are required
to manufacture sufficient microdialysis perfusion fluid to
study tens of patients. Furthermore, this technique allows the
downstream metabolism of glucose to be evaluated beyond
that previously afforded by arterio-venous studies and PET.
The intravenous delivery of exogenous 13C-labelled sub-
strates can be combined with in vivo magnetic resonance
spectroscopy (MRS) to investigate cerebral metabolism in
humans, although this technique has not yet been applied to
TBI patients. In vivo 13C-MRS, performed on a conventional
MRI scanner with specialised coils, has been used to follow
the rate of change of fractional enrichment of a metabolic
product, performed in real time, after intravenous delivery of
the substrate. In this way, infusing 1-13C glucose and measur-
ing the rate of fractional enrichment for glutamate C4 has been
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used in metabolic modelling data analysis to calculate TCA
cycle kinetics in healthy volunteers (Mason et al. 1995;
Moreno et al. 2001; Gruetter et al. 2002; Rothman et al.
2011). The extension to TBI patients of such in vivo 13C
MRS methodology will enable calculation of rates of metab-
olism beyond that previously afforded by FDG-PET, which
only provides kinetic data on glucose uptake and phosphory-
lation, and will thus permit more in-depth evaluation of me-
tabolism after TBI.
The TCA cycle is inherently mitochondrial, and the above
13C-labelling strategies with measurements by ex vivo high
resolution NMR and in vivo MRS are thus relevant to mito-
chondrial activity in the human brain. In particular, microdi-
alysis studies with 13C-labelled lactate and acetate have al-
ready demonstrated TCA cycle utilisation of these substrates
in TBI patients’ brains (Gallagher et al. 2009). An important
implication of these results is that mitochondria are evidently
still active in injured brain, even in sites close to focal lesions.
So although TBI brain is often regarded as “glycolytic”, and
“mitochondrial dysfunction” invoked, the mitochondria are
certainly functioning, although there is obviously much scope
for debate about how healthy or otherwise they are. Also
relevant in this context are results from a combined FDG-
PET and microdialysis study in 17 TBI patients (Hutchinson
et al. 2009). In that study, there was significant positive linear
relationship between CMRglc and levels of lactate (r=0.778,
p<0.0001) and pyruvate (r=0.799, p<0.0001), but not with
the lactate/pyruvate ratio. This argued against a shift towards
“anaerobic” metabolism at least in this cohort of patients.
Taken together, the results imply that therapeutic strategies
aimed at supporting or rescuing mitochondria may be helpful
in TBI patients. Possibly relevant are experimental TBI stud-
ies in which Cyclosporin A, which inhibits opening of the
mitochondrial permeability transition pore (MPTP), restored
mitochondrial membrane potential, reduced tissue damage
and improved neurological outcomes (Scheff and Sullivan
1999; Alessandri et al. 2002). Very recently, another experi-
mental TBI study reported neuroprotective effects with im-
proved behavioural outcomes for N-acetylcysteine amide
(NACA), apparently due to maintenance of mitochondrial
glutathione and mitochondrial bioenergetics, and to reduction
in oxidative damage (Pandya et al. 2014). These or other
mitochondrial support and rescue strategies may prove useful
in future development of novel therapies for TBI. We have
Fig. 5 Carbon-13 labelling patterns after administration of 1-13C glu-
cose: When the first carbon of glucose (C1) is 13C, the resulting pyruvate
maintains the 13C as the third carbon (C3). Glycolysis converts one
molecule of glucose into two molecules of pyruvate and so only one of
the two 3-carbon chain length pyruvate molecules will contain 13C.
Pyruvate can be converted to lactate, by the action of lactate dehydroge-
nase. Alternatively, through the action of pyruvate dehydrogenase on
pyruvate, acetyl-CoA is produced containing just a 2-carbon backbone
with one of the carbons (C1, the carboxylate carbon of pyruvate) lost as
carbon dioxide. The 2 carbons of acetyl-CoA are then condensed with
oxaloacetate and continue in the TCA cycle, ultimately emerging as
amino acid spin-offs or as carbon dioxide. The main products identifiable
with NMR (in animal brain tissue extracts ex vivo) or MRS (in human or
animal brain in vivo) include glutamine, glutamate, GABA and aspartate.
The C1 of a glucose molecule will become the C4 of glutamate and
glutamine on the first turn of the TCA cycle. Subsequent turns of the TCA
cycle will result in the 13C label shifting to the C3 or C2 of glutamate and
glutamine. Hence, it is possible to determine, through the relative enrich-
ment of the C4, C3, or C2 carbons, the proportion of glutamate or
glutamine produced on the first turn of the TCA and subsequent cycles.
In this way, 13C-NMR provides a convenient way to study the transfor-
mation of the carbon skeleton that takes place during the metabolism of
glucose. The relative proportions of 13C incorporation at the different
carbon positions of the relevant metabolites have been used in numerous
studies to compare pathway activities. This schematic diagram is based
on results obtained with singly labelled substrates, by Gallagher et al.
(2009), Tyson et al. (2003) and Sampol et al. (2013) Abbreviations: PDH
pyruvate dehydrogenase, PC, pyruvate carboxylase, ME malic enzyme
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Fig. 6 Illustrative 13C-NMR spectra achieved by ex vivo NMR of
microdialysate after delivery of 3-13C lactate and 1,2-13C2 glucose to
TBI patients: Upper panel: a and b Examples of 13C NMR spectra of
brain microdialysates from a TBI patient, who received perfusion with
3-13C lactate (4 mM) by microdialysis catheters via a craniotomy (CTO);
red stars indicate 13C signals for glutamine C4, C3 and C2 indicating
metabolism via TCA cycle. c 13C NMR spectrum of the 3-13C lactate
substrate solution prior to perfusing. d 13C NMR spectrum of brain
microdialysate from an unlabelled patient. For further details, see
Gallagher et al. (2009). Figure originally published in Brain (Gallagher
et al. 2009). Lower panel: Examples of 13C NMR spectra of brain
microdialysates from patients who received 1,2-13C2 glucose (4 mM)
perfused via the microdialysis catheter. Uninjured brain is normal-
appearing brain in a patient operated on for a benign tumour elsewhere
in the brain. TBI brain is from a patient with a diffuse injury. The part of
the spectrum illustrated in each case is for the C3 carbon of lactate. Also
present in this part of the spectrum is one of the signals due to the internal
standard DSS (2,2-dimethyl-2-silapentane-5-sulfonate sodium salt). The
remainder of the spectrum (including themain DSS signal at 0 ppm) is not
shown. The C3 doublet indicated by red stars represents lactate doubly
labelled with 13C, produced by glycolysis; the C3 signal for 13C is split
into 2 peaks by coupling to 13C also present at the neighbouring C2
position within the same molecule. The C3 singlet indicated by green
stars represents lactate singly labelled with 13C, produced via the PPP.
Figure originally published in European Journal of Pharmaceutical Sci-
ences (Carpenter et al. 2014)
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already mentioned (see above) the relevance of 13C labelling
to address the TCA cycle in clinical studies of TBI patients. In
addition, 31P in vivo MRS (discussed in “Proton & phospho-
rus magnetic resonance spectroscopy” section below) has the
potential to be useful in future clinical trials of drugs directed
at improvingmitochondrial function by assessing the response
of cellular ATP levels to treatment.
Proton & phosphorus magnetic resonance spectroscopy
Magnetic resonance spectroscopy (MRS) is an in vivo tech-
nique carried out on suitably equipped MRI scanners. MRS
was developed from the principles of NMR and can identify
metabolites relevant to disordered energy metabolism in
voxels and regions of interest (ROIs) defined on the MRI
scan. The most commonly used nucleus is the proton (1H);
however other nuclei that possess nuclei spin values of 1/2,
and so in essence behave like miniature bar magnets, can also
be used in MRS. 1H and phosphorus (31P) MRS have been
used to interrogate energymetabolism after TBI. An important
advantage of 1H and 31P MRS techniques is their ability to
yield biochemical information non-invasively without the
need for tracers. Different localisation techniques are used to
produce spectra that represent either a broad region of the
brain (e.g. a hemispherical ROI relative to the plane of a
surface coil) or individual voxels (e.g. if a head-coil is used).
The sensitivity of 1H MRS is sufficient to allow the iden-
tification of N-acetylaspartate (NAA, typically the largest
signal), choline-containing phospholipids, creatine and phos-
phocreatine, lactate, myo-inositol, glutamate, GABA, and
lipids. The appearance of signals in 1H MRS is influenced
by choice of echo time (TE). In particular, lactate signals are
can appear positive, disappear or appear inverted depending
on the duration of TE. Typically, in 1H MRS levels of lactate
and other metabolites are expressed as ratios to creatine;
absolute and accurate quantification of metabolite signals is
more difficult (Marino et al. 2007, 2010).
The most relevant 1H MRS metabolite for demonstrating
perturbed energy metabolism after TBI is lactate. Increases in
lactate have been demonstrated after TBI particularly in chil-
dren. In normal controls, a lactate peak is not readily detectable.
In a study of 51 infants and children with TBI, 91 % of infants
and 80 % of children with a poor outcome demonstrated a
lactate MRS peak in the grey matter of the occipital lobe
(Ashwal et al. 2000). A later study also showed that the
presence of a lactate peak, this timewith theMRS voxel located
in the corpus callosum and frontal white matter, was predictive
of a poor outcome in children (Aaen et al. 2010). The ability to
detect lactate with MRS after TBI in children has not been
consistently replicated in studies of adult patients. Several
studies that demonstrate other markers of disordered biochem-
istry such as a reduced NAA/creatine ratio and an increased
choline/creatine ratio did not find a detectable lactate signal in
their patients (Cecil et al. 1998; Garnett et al. 2000). This may
be due to the particular echo times used or the timing post-
injury of the MRS scan. In support of this, MRS performed
within 72 h of TBI was able to demonstrate a lactate peak in
five of ten patients and this correlated with GCS at presentation
and clinical outcome (Marino et al. 2007).
Adenosine triphosphate (ATP) an important end-point of
cellular energy metabolism, and phosphocreatine (PCr), a read-
ily mobilised store of high-energy phosphate, are compounds
that can be measured in vivo using 31P MRS. When mitochon-
drial ATP synthesis is running normally, the PCr store is well
stocked; when ATP synthesis is struggling to meet demand the
PCr store runs down. 31P MRS has been used to determine the
molar ratio of PCr to inorganic phosphate (PCr/Pi) and the PCr/
ATP ratio as indicators of oxidative phosphorylation status and
mitochondrial function (Eleff et al. 1984; Hetherington et al.
2001). Both PCr/Pi and PCr/ATP ratios are notionally easier to
measure than absolute concentrations and have been measured
in both chronic and acute TBI patients (Cadoux-Hudson et al.
1990; Garnett et al. 2001). Garnett et al. (2001) found increased
PCr/Pi ratio and reduced Pi/ATP in predominantly normal
appearing white matter of seven patients scanned between 2
and 21 days after severe TBI suggesting adequate mitochon-
drial energy metabolism. However, animal studies using 31P
MRS after FPI or weight-drop model of diffuse injury reveal a
decline in PCr/Pi suggestive of a failure of mitochondrial
function (Vink et al. 1987; Heath and Vink 1995). More studies
are needed to determine whether the differences between clin-
ical and experimental findings are due to differences in pH, free
intracellular magnesium concentrations, or cellularity, all of
which might alter the measurement of phosphate compounds
using 31P MRS.
Summary and conclusions
Understanding cerebral energy metabolism is complicated by
a series of specialisations that are unique to the brain. The
brain exists in its own unique chemical environment, shielded
by the blood brain barrier; it has high demands for energy and
is vulnerable to reduced substrate provision. Unlike other
organs, there are limited glycogen stores and the energy
generating pathways are intrinsically linked to its main func-
tion of neurotransmission. Increasingly recognised are the
functional differences in how the two main cell types, neurons
and astrocytes, use glucose.
Changes to glucose metabolism that follow TBI appear to
be largely independent of ischaemia. PET studies, both alone
and in combination with microdialysis, suggest that ischae-
mia, when it occurs, is only detectable to any great extent in
the first few hours after TBI or when CBF is challenged by
hyperventilation or marked falls in CPP. More relevant is a
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change in the cellular utilisation of glucose with an increase in
the proportion of glucose that is “anaerobically” metabolised.
More studies are needed to determine whether this simply
serves an increased requirement for a rapid supply of energy,
maintaining the availability of high-energy phosphate com-
pounds, or whether greater amounts of glucose are used for
non-energy generating, reparative and biosynthetic roles such
as the PPP. Along with a change in the metabolic role of
glucose, lactate appears to become important as a metabolic
substrate, imported from the circulation and oxidatively
metabolised via the TCA cycle.
The methods discussed in this review are not yet employed
widely in the clinical setting. They remain predominantly
research tools but have the potential to become useful clini-
cally. Choice of technique is inevitably dictated by what is
available locally. In the present review we have gathered
together findings from several technologies, and have
discussed in each of the above sections what the particular
technique is good for, and any limitations and caveats. A
summary of methodology is also included (Table 1). A
multi-technique approach is usually more powerful than a
single methodology. Debate still exists on how best to inte-
grate results from multiple techniques, including how to fit
together “snapshot” techniques (such as scans) with data
collected over an extended timescale of days (e.g. microdial-
ysis), how to integrate global, regional and focal measures,
and intracellular vs. extracellular information. Amalgamation
of these diverse components may emerge from advances in
data handling methods, including multivariate methods and
machine learning technologies, when applied to the large
databases that are growing in specialist centres and as a result
of multicentre collaborations.
The precise biological questions to be addressed need to be
appropriate to the techniques available. MRS and PETare suited
to observing regional changes in metabolism and can demon-
strate changes associated with structural lesions such as contu-
sions. Currently, PET is limited by the availability of PET
ligands, while MRS is limited by MR technology, improve-
ments in which will lead to greater spatial resolution and the
ability to interrogate all areas of the brain including deep struc-
tures such as the brain stem. This offers the potential to better
characterise the injured brain, assisting with outcome prediction,
and helping to direct clinical and rehabilitation management
decisions. However, transferring patients from neurocritical care
wards for PET or MRS scans is not a risk free undertaking,
limiting the serial use of these investigations, so the time-variant
aspect of such data is relatively unexplored and these scanning
techniques are effectively snapshots for the duration of the scan.
Moreover, only a few centres worldwide have scanners adjacent
to neurocritical care wards and the necessary expertise for fully
ventilated patients to routinely receive PET and MRI scans.
AV measurements and microdialysis are much more suited
to following longitudinal changes. Moreover, the relative ease
of obtaining data in the early stages following injury means
they are particularly well placed to direct interventions and
guide treatment. In particular, brain chemistry monitored by
microdialysis has been demonstrated in large numbers of pa-
tients to relate statistically to clinical outcome and there is
increasing evidence of how it is influenced by different thera-
peutic interventions. Hence, microdialysis is well placed to
monitor glucose delivery to the brain, assist in the management
of systemic glucose levels, and optimise CPP. Future clinical
studies are needed to establish the role of microdialysis-directed
interventions alongside ICP/CPP-guided management.
The current aims of TBI management focus on ICP/CPP-
guided management to maintain adequate cerebral perfusion.
The development of methods that sense metabolic changes
means that we can tailor our interventions tomaintain sufficient
energy metabolism and ultimately limit the natural end-point of
metabolic failure, cell death. The ability to monitor the chang-
ingmetabolism of glucose after TBI raises interesting questions
about the potential to manipulate these different pathways and
reduce secondary injury. Multimodality monitoring, including
microdialysis measures of brain chemistry, simultaneously
with local PbtO2, together with ICP and derived pressure
parameters such as CPP and PRx, is not only useful in standard
neurocritical care to assist in patient management but is also a
research approach that is being utilised to explore metabolic
changes in the injured brain. Multimodality continuous moni-
toring is complemented by specialised scanning techniques
(including PET, MRI and MRS), which provide a snapshot of
the brain. The ability to understand and modulate glucose
metabolism in the brain is likely to be a crucial factor in
achieving the best clinical outcomes for TBI patients.
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